-
-
Login
CamDiab’s automated insulin delivery technology gets regulatory progress toward fully closed-loop system.
A global survey by Roche of more than 4,300 people with diabetes has highlighted the daily planning, uncertainty and mental effort involved in managing the condition.
News from Portal Diabetes that new medtech for an implantable insulin pump has reached an early regulatory milestone in the US.
After gaining a CE mark in January, the rollout of Eversense 365 implantable sensor, designed to last for a full year is expected in 2026.
Medtronic officially spins off diabetes business to become standalone company MiniMed. Includes news of regulatory updates for the MiniMed insulin pump system.
News of Omnipod Discover app to organise insulin and glucose data plus rollout of Omnipod 5 in the Middle East.
An update on Dexcom's 2026 plans with changes in senior leadership and a push for wider access to CGM technology.
Reporting on the latest from Beta Bionics following FDA warning letter and insider share sales.
Medtronic has announced 3 milestones that broaden MiniMed 780G hybrid-closed loop system in the USA. The news covers Medicare access, new insulin options, and an expansion to people with insulin-requiring type 2 diabetes.
Medtronic has received FDA clearance for a new mobile app called MiniMed Go, designed to connect its smart insulin pens with the Instinct sensor by Abbott.
Abbott receives warning letter for FreeStyle Libre sensors from the FDA following an inspection. The letter focuses on problems with Abbott's tests and verification of accuracy of their CGMs.
Details of Insulet's long-term vision and new details about Omnipod 6, alongside upgrades to existing systems and a fully closed-loop option for people with type 2 diabetes.
